Cushing's disease Pipeline 2025: Groundbreaking Clinical Advancements by 4+ Global Leaders - DelveInsight | Featuring Relacorilant, SPI 62, CRN-04894

With Cushing's disease reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Cushing's disease pipeline comprises 4+ pharmaceutical and biotech companies actively developing 4+ therapeutic candidates targeting Cushing's disease. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Cushing's disease Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders, including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Cushing's disease Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Cushing's disease Drug Development @ https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Cushing's disease Pipeline Report:

DelveInsight's Cushing's disease pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Cushing's disease treatment.
In April 2025, the FDA approved a supplemental New Drug Application (sNDA) for Isturisa (osilodrostat), expanding its label to treat endogenous hypercortisolemia in adults with Cushing's syndrome when surgery isn't possible or wasn't curative. Previously approved in March 2020 for Cushing's disease, this broader indication is supported by data from more than 350 patients across LINC‐3, LINC‐4, LINC‐6, and LINC‐7 trials.
In March 2025, Corcept Therapeutics submitted a New Drug Application (NDA) for relacorilant, a selective glucocorticoid receptor modulator, aiming to treat endogenous hypercortisolism (Cushing's syndrome). The filing is based on positive results from Phase 3 trials (GRACE, GRADIENT), including significant improvements in hypertension, hyperglycemia, and other cortisol-driven symptoms.
Key Cushing's disease companies such as Relacorilant, SPI 62, CRN-04894, and others are evaluating new drugs for Cushing's disease to improve the treatment landscape.
Promising Cushing's disease pipeline therapies in various stages of development include Relacorilant, and others.

Cushing's disease Overview:

Cushing's syndrome, also known as hypercortisolism, is a hormonal disorder caused by prolonged exposure to elevated levels of cortisol in the body. The condition can be classified into two main types: ACTH-dependent and ACTH-independent forms. It is considered rare and most often affects adults between the ages of 20 and 50. In ACTH-dependent cases, a pituitary tumor frequently leads to excessive ACTH production, disrupting the normal feedback regulation of the hypothalamic-pituitary-adrenal (HPA) axis and resulting in overproduction of cortisol by the adrenal glands. This prolonged cortisol excess leads to a range of health issues, including comorbidities, higher mortality risk, and reduced quality of life.

Common symptoms include central weight gain, facial rounding (moon face), thinning limbs, fragile skin that bruises easily, acne, hypertension, type 2 diabetes, muscle weakness, and psychological symptoms such as anxiety and depression. Women may experience irregular menstrual cycles and excessive hair growth, while men may have reduced fertility, and children may show stunted growth. The syndrome can stem from prolonged corticosteroid use, pituitary tumors, or adrenal gland disorders.

In ACTH-independent Cushing's syndrome, the symptoms arise directly from high levels of circulating cortisol. In contrast, ACTH-dependent forms may also involve skin and gum hyperpigmentation, due to ACTH's indirect stimulation of melanin production. Prompt diagnosis and treatment are essential to manage symptoms and prevent serious complications.

Download the Cushing's disease sample report to know in detail about the Cushing's disease treatment market @ https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cushing's disease Pipeline Analysis
The Cushing's disease pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Cushing's disease Market.

Categorizes Cushing's disease therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Cushing's disease drugs under development based on:

Stage of development

Cushing's disease Route of administration

Target receptor

Monotherapy vs. combination therapy

Cushing's disease Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Cushing's disease Licensing agreements

Funding and investment activities supporting future Cushing's disease market advancement.

Unlock key insights into emerging Cushing's disease therapies and market strategies here: https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cushing's disease Emerging Drugs

Relacorilant: Corcept Therapeutics

Relacorilant (CORT 125134) is a non-steroidal, selective antagonist of the glucocorticoid receptor type II (GR II). It works by competitively binding to these receptors, thereby blocking their activation. This action prevents the translocation of the ligand-receptor complex to the cell nucleus and stops the expression of genes regulated by glucocorticoids. Corcept Therapeutics is investigating relacorilant for use in several serious conditions, including Cushing's syndrome as well as adrenal, ovarian, and pancreatic cancers.

The drug has been granted orphan drug designation in the U.S. for both Cushing's syndrome and pancreatic cancer, and in both the U.S. and EU for Cushing's syndrome. In December 2024, Sparrow Pharmaceuticals submitted a New Drug Application (NDA) to the U.S. FDA for relacorilant, aiming to secure approval for the treatment of endogenous hypercortisolism (Cushing's syndrome).

Cushing's disease Pipeline Therapeutic Assessment

Cushing's disease Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Cushing's disease By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cushing's disease Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Cushing's disease Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Cushing's disease therapies and key Cushing's disease companies: https://www.delveinsight.com/sample-request/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Cushing's disease Current Treatment Patterns
4. Cushing's disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cushing's disease Late-Stage Products (Phase-III)
7. Cushing's disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cushing's disease Discontinued Products
13. Cushing's disease Product Profiles
14. Cushing's disease Key Companies
15. Cushing's disease Key Products
16. Dormant and Discontinued Products
17. Cushing's disease Unmet Needs
18. Cushing's disease Future Perspectives
19. Cushing's disease Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Cushing's disease pipeline reports offerings: https://www.delveinsight.com/report-store/cushings-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.